Articles by Randall C Willis

A decade on, nanomedicines may finally be ready to jump to the fore

Physics, chemistry and informatics combine to push life into the 4th dimension

Randall C Willis talks about what's wrong with the disease models we currently use to discover and develop therapeutics and points us in the general direction of where we need to go to get models more in line with reality

Despite being a predominantly scientific conference, ISSCR 2014 dedicated several sessions to the business side of stem cell technologies and therapeutics development

Because of the significant costs associated with stem cell production scale-up, one of the challenges of clinical development is the potentially crippling effect of late-stage failure and the inability to leverage some of that financial risk by accessing patient populations before the end of Phase 3 studies

A good percentage of ISSCR 2014 was dedicated to the development of model systems that better reflected human pathophysiology

The growing noise about the prospects of stem cell therapies has prompted a disturbing trend, according to a number of researchers at ISSCR 2014: the increasing availability of unproven treatments for patients

A little over a year ago, we published a special report on the challenges facing new oncology drugs as they moved through the clinical trial process. This time, Randall C Willis looks further into this challenge by examining the clinical trial process itself

It might be time to start looking at the reasons why some people don't get certain diseases despite so many factors saying they should. Such an approach might help lead us to new ways of preventing or curing what ails us.

Developing world diagnostic solutions might make emerging markets merging markets

Striking a balance between the needs of the scientific process in health sciences research and the legitimate desires of ailing patients is a difficult thing. Whether or not we can or should change the system, we should still consider the toll it can take on people

The pending patent cliff means companies need to take a second look